TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic devices and anti-body drugs. The company was founded in 2011 and is based in Taipei, Taiwan.
Metrics to compare | 6580 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6580PeersSector | |
|---|---|---|---|---|
P/E Ratio | −16.8x | −35.7x | −0.6x | |
PEG Ratio | −0.59 | −0.35 | 0.00 | |
Price/Book | 4.1x | 5.0x | 2.6x | |
Price / LTM Sales | 153.9x | 72.4x | 3.4x | |
Upside (Analyst Target) | - | 0.0% | 42.5% | |
Fair Value Upside | Unlock | −19.0% | 5.8% | Unlock |